{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:39Z","timestamp":1792788339063,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"American-Italian Cancer Foundation Post-Doctoral Research Fellowship"},{"name":"Associazione Italiana Ricerca sul Cancro and Fondazione CR Firenze","id":[{"id":"https:\/\/ror.org\/049wkn258","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019962","name":"Cancer Couch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019962","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hope Scarves"},{"name":"Jamieson Family Fund for Early Career Breast Cancer Researchers","id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Elaine and Eduardo Saverin Foundation"},{"name":"National Cancer Institute","award":["P01 CA250959"],"award-info":[{"award-number":["P01 CA250959"]}]},{"name":"National Cancer Institute","award":["P01 CA250959-04"],"award-info":[{"award-number":["P01 CA250959-04"]}]},{"DOI":"10.13039\/100019664","name":"Expect Miracles Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019664","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert A. and Ren\u00e9e E. Belfer Family Foundation","id":[{"id":"https:\/\/ror.org\/027ezef52","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01CA237414"],"award-info":[{"award-number":["5R01CA237414"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DFCI Susan F. Smith Center for Women\u2019s Cancers"},{"name":"Breast & Gynecologic Cancer Innovation Awards"},{"name":"Melanie Rosay fund for Breast Cancer research","id":[{"id":"https:\/\/ror.org\/03xzf6x18","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Maor Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-026-01690-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:23:48Z","timestamp":1782555828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["ESR1 mutations and CDK4\/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance"],"prefix":"10.1186","volume":"18","author":[{"given":"Cristina","family":"Guarducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Abravanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwajit","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella Cohen","family":"Feit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hermida-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Heraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Munoz Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Elisa","family":"Garcia Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kurnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Gomez Tejeda Zanudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Feiglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Sicinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"Polyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cloud","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chip","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Michor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinath","family":"Jeselsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"2","key":"1690_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21(2):89\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"1690_CR2","first-page":"923","volume":"2","author":"R Hui","year":"1996","unstructured":"Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, et al. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res. 1996;2(6):923\u20138.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1690_CR3","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1690_CR4","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1038\/s41467-018-04413-3","volume":"9","author":"SW Fanning","year":"2018","unstructured":"Fanning SW, Hodges-Gallagher L, Myles DC, Sun R, Fowler CE, Plant IN, et al. Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity. Nat Commun. 2018;9(1):2368.","journal-title":"Nat Commun"},{"issue":"1","key":"1690_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41467-025-55914-x","volume":"16","author":"Z Kan","year":"2025","unstructured":"Kan Z, Wen J, Bonato V, Webster J, Yang W, Ivanov V, et al. Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4\/6 inhibitors. Nat Commun. 2025;16(1):932.","journal-title":"Nat Commun"},{"issue":"11","key":"1690_CR6","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390\u2013403.","journal-title":"Cancer Discov"},{"issue":"6","key":"1690_CR7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the Hippo pathway. Cancer Cell. 2018;34(6):893\u2013905.","journal-title":"Cancer Cell"},{"issue":"23","key":"1690_CR8","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-22-2305","volume":"28","author":"J Tsuji","year":"2022","unstructured":"Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, et al. Clinical efficacy and whole-exome sequencing of liquid biopsies in a phase IB\/II study of bazedoxifene and palbociclib in advanced hormone receptor-positive breast cancer. Clin Cancer Res. 2022;28(23):5066\u201378.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1690_CR9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.","journal-title":"Nat Commun"},{"issue":"1","key":"1690_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","volume":"2","author":"AC Watt","year":"2021","unstructured":"Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, et al. CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021;2(1):34\u201348.","journal-title":"Nat Cancer"},{"issue":"7","key":"1690_CR11","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","volume":"20","author":"R Jeselsohn","year":"2014","unstructured":"Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor\u2013positive breast cancer. Clin Cancer Res. 2014;20(7):1757\u201367.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1690_CR12","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439\u201345.","journal-title":"Nat Genet"},{"issue":"2","key":"1690_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","volume":"33","author":"R Jeselsohn","year":"2018","unstructured":"Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell. 2018;33(2):173-86 e5.","journal-title":"Cancer Cell"},{"issue":"25","key":"1690_CR14","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1690_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2300231","DOI":"10.1056\/EVIDoa2300231","volume":"3","author":"MR Lloyd","year":"2024","unstructured":"Lloyd MR, Brett JO, Carmeli A, Weipert CM, Zhang N, Yu J, et al. CDK4\/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid. 2024;3(5):EVIDoa2300231.","journal-title":"NEJM Evid"},{"issue":"6","key":"1690_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","volume":"18","author":"JA Katzenellenbogen","year":"2018","unstructured":"Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandarlapaty S. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018;18(6):377\u201388.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1690_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367\u201377.","journal-title":"Lancet Oncol"},{"key":"1690_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502929","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/nejmoa2502929.","journal-title":"N Engl J Med"},{"issue":"8","key":"1690_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","volume":"26","author":"M Hafner","year":"2019","unstructured":"Hafner M, Mills CE, Subramanian K, Chen C, Chung M, Boswell SA, et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol. 2019;26(8):1067-80 e8.","journal-title":"Cell Chem Biol"},{"issue":"8","key":"1690_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10(8):1174\u201393.","journal-title":"Cancer Discov"},{"key":"1690_CR21","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756.","journal-title":"Breast"},{"issue":"1","key":"1690_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"18","key":"1690_CR23","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1093\/bioinformatics\/btab135","volume":"37","author":"A Graubert","year":"2021","unstructured":"Graubert A, Aguet F, Ravi A, Ardlie KG, Getz G. RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics. 2021;37(18):3048\u201350.","journal-title":"Bioinformatics"},{"key":"1690_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"1690_CR25","doi-asserted-by":"publisher","first-page":"lqaa078","DOI":"10.1093\/nargab\/lqaa078","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Parmigiani G, Johnson WE. ComBat-seq: batch effect adjustment for RNA-seq count data. NAR Genom Bioinform. 2020;2(3):lqaa078.","journal-title":"NAR Genom Bioinform"},{"issue":"43","key":"1690_CR26","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7269","key":"1690_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"7269","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 7269;462(7269):108\u201312.","journal-title":"Nature"},{"issue":"14","key":"1690_CR28","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754\u201360.","journal-title":"Bioinformatics"},{"issue":"9","key":"1690_CR29","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303.","journal-title":"Genome Res"},{"issue":"4","key":"1690_CR30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714\u201326.","journal-title":"Cell"},{"issue":"5","key":"1690_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30(5):413\u201321.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1690_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s43018-023-00533-y","volume":"4","author":"I Leshchiner","year":"2023","unstructured":"Leshchiner I, Mroz EA, Cha J, Rosebrock D, Spiro O, Bonilla-Velez J, et al. Inferring early genetic progression in cancers with unobtainable premalignant disease. Nat Cancer. 2023;4(4):550\u201363.","journal-title":"Nat Cancer"},{"issue":"1","key":"1690_CR33","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1038\/s41467-024-45835-6","volume":"15","author":"J Gomez Tejeda Zanudo","year":"2024","unstructured":"Gomez Tejeda Zanudo J, Barroso-Sousa R, Jain E, Jin Q, Li T, Buendia-Buendia JE, et al. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial. Nat Commun. 2024;15(1):2446.","journal-title":"Nat Commun"},{"issue":"5","key":"1690_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm.3841","volume":"21","author":"HE Bhang","year":"2015","unstructured":"Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015;21(5):440\u20138.","journal-title":"Nat Med"},{"issue":"26","key":"1690_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.21105\/joss.00765","volume":"3","author":"H Drost","year":"2018","unstructured":"Drost H. Philentropy: information theory and distance quantification with R. J Open Source Softw. 2018;3(26):765\u2013765.","journal-title":"J Open Source Softw"},{"key":"1690_CR36","first-page":"65","volume":"6","author":"S Holm","year":"1979","unstructured":"Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65\u201370.","journal-title":"Scand J Stat"},{"issue":"3","key":"1690_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213\u20139.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1690_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12859-018-2527-1","volume":"19","author":"M Cornwell","year":"2018","unstructured":"Cornwell M, Vangala M, Taing L, Herbert Z, Koster J, Li B, et al. VIPER: visualization pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinformatics. 2018;19(1):135.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"1690_CR39","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511\u20135.","journal-title":"Nat Biotechnol"},{"issue":"16","key":"1690_CR40","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","volume":"28","author":"L Wang","year":"2012","unstructured":"Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28(16):2184\u20135.","journal-title":"Bioinformatics"},{"issue":"12","key":"1690_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"key":"1690_CR42","doi-asserted-by":"publisher","unstructured":"Marques de Almeida F, Peltzer A, Sturm G, heylf, Botvinnik O, nf-core bot, et al. nf-core\/scrnaseq: 2.7.1. Zenodo; 2024. https:\/\/doi.org\/10.5281\/zenodo.3568187.","DOI":"10.5281\/zenodo.3568187"},{"issue":"3","key":"1690_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276\u20138.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"1690_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41592-018-0046-7","volume":"15","author":"B Gruning","year":"2018","unstructured":"Gruning B, Dale R, Sjodin A, Chapman BA, Rowe J, Tomkins-Tinch CH, et al. Bioconda: sustainable and comprehensive software distribution for the life sciences. Nat Methods. 2018;15(7):475\u20136.","journal-title":"Nat Methods"},{"issue":"16","key":"1690_CR45","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1093\/bioinformatics\/btx192","volume":"33","author":"F da Veiga Leprevost","year":"2017","unstructured":"da Veiga Leprevost F, Gruning BA, Alves Aflitos S, Rost HL, Uszkoreit J, Barsnes H, et al. BioContainers: an open-source and community-driven framework for software standardization. Bioinformatics. 2017;33(16):2580\u20132.","journal-title":"Bioinformatics"},{"issue":"4","key":"1690_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"1","key":"1690_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13059-019-1670-y","volume":"20","author":"A Srivastava","year":"2019","unstructured":"Srivastava A, Malik L, Smith T, Sudbery I, Patro R. Alevin efficiently estimates accurate gene abundances from dscRNA-seq data. Genome Biol. 2019;20(1):65.","journal-title":"Genome Biol"},{"key":"1690_CR48","doi-asserted-by":"crossref","unstructured":"Stolarczyk M, Reuter VP, Smith JP, Magee NE, Sheffield NC. Refgenie: a reference genome resource manager. Gigascience. 2020;9(2):giz149.","DOI":"10.1093\/gigascience\/giz149"},{"issue":"2","key":"1690_CR49","doi-asserted-by":"publisher","first-page":"lqab036","DOI":"10.1093\/nargab\/lqab036","volume":"3","author":"M Stolarczyk","year":"2021","unstructured":"Stolarczyk M, Xue B, Sheffield NC. Identity and compatibility of reference genome resources. NAR Genom Bioinform. 2021;3(2):lqab036.","journal-title":"NAR Genom Bioinform"},{"issue":"18","key":"1690_CR50","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1093\/nar\/gkz622","volume":"47","author":"A Zhu","year":"2019","unstructured":"Zhu A, Srivastava A, Ibrahim JG, Patro R, Love MI. Nonparametric expression analysis using inferential replicate counts. Nucleic Acids Res. 2019;47(18):e105.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1690_CR51","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41467-018-05083-x","volume":"9","author":"JA Griffiths","year":"2018","unstructured":"Griffiths JA, Richard AC, Bach K, Lun ATL, Marioni JC. Detection and removal of barcode swapping in single-cell RNA-seq data. Nat Commun. 2018;9(1):2667.","journal-title":"Nat Commun"},{"key":"1690_CR52","doi-asserted-by":"crossref","unstructured":"Lun ATL, Riesenfeld S, Andrews T, Dao TP, Gomes T, participants in the 1st Human Cell Atlas J, et al. EmptyDrops: distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 2019;20(1):63.","DOI":"10.1186\/s13059-019-1662-y"},{"issue":"2","key":"1690_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42(2):293\u2013304.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1690_CR54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13059-019-1861-6","volume":"20","author":"FW Townes","year":"2019","unstructured":"Townes FW, Hicks SC, Aryee MJ, Irizarry RA. Feature selection and dimension reduction for single-cell RNA-seq based on a multinomial model. Genome Biol. 2019;20(1):295.","journal-title":"Genome Biol"},{"issue":"1","key":"1690_CR55","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13059-020-02109-w","volume":"21","author":"FW Townes","year":"2020","unstructured":"Townes FW, Hicks SC, Aryee MJ, Irizarry RA. Author correction: feature selection and dimension reduction for single-cell RNA-seq based on a multinomial model. Genome Biol. 2020;21(1):179.","journal-title":"Genome Biol"},{"key":"1690_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae494","author":"E Weine","year":"2024","unstructured":"Weine E, Carbonetto P, Stephens M. Accelerated dimensionality reduction of single-cell RNA sequencing data with fastglmpca. Bioinformatics. 2024. https:\/\/doi.org\/10.1093\/bioinformatics\/btae494.","journal-title":"Bioinformatics"},{"key":"1690_CR57","doi-asserted-by":"crossref","unstructured":"Zappia L, Oshlack A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience. 2018;7(7):giy083.","DOI":"10.1093\/gigascience\/giy083"},{"issue":"17","key":"1690_CR58","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1093\/nar\/gks461","volume":"40","author":"D Wu","year":"2012","unstructured":"Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012;40(17):e133.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1690_CR59","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1690_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325.","journal-title":"Cell Syst"},{"issue":"1","key":"1690_CR61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini YaH","year":"1995","unstructured":"Benjamini YaH Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B (Methodol). 1995;57(1):289\u2013300.","journal-title":"J Roy Stat Soc Ser B (Methodol)"},{"issue":"20","key":"1690_CR62","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-21-3186","volume":"82","author":"A Nardone","year":"2022","unstructured":"Nardone A, Qiu X, Spisak S, Nagy Z, Feiglin A, Feit A, et al. A distinct chromatin state drives therapeutic resistance in invasive lobular breast cancer. Cancer Res. 2022;82(20):3673\u201386.","journal-title":"Cancer Res"},{"issue":"12","key":"1690_CR63","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/nmeth.2688","volume":"10","author":"JD Buenrostro","year":"2013","unstructured":"Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10(12):1213\u20138.","journal-title":"Nat Methods"},{"issue":"4","key":"1690_CR64","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.gpb.2020.11.007","volume":"19","author":"X Qiu","year":"2021","unstructured":"Qiu X, Feit AS, Feiglin A, Xie Y, Kesten N, Taing L, et al. CoBRA: containerized bioinformatics workflow for reproducible ChIP\/ATAC-seq analysis. Genomics Proteomics Bioinformatics. 2021;19(4):652\u201361.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"1690_CR65","doi-asserted-by":"crossref","unstructured":"Taing L BG, Cousins C, et al. CHIPS: A Snakemake pipeline for quality control and reproducible processing of chromatin profiling data. F1000Research. 2021;10:517.","DOI":"10.12688\/f1000research.52878.1"},{"issue":"9","key":"1690_CR66","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.","journal-title":"Genome Biol"},{"issue":"12","key":"1690_CR67","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1038\/nprot.2013.150","volume":"8","author":"S Wang","year":"2013","unstructured":"Wang S, Sun H, Ma J, Zang C, Wang C, Wang J, et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat Protoc. 2013;8(12):2502\u201315.","journal-title":"Nat Protoc"},{"issue":"8022","key":"1690_CR68","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","volume":"631","author":"GS Franca","year":"8022","unstructured":"Franca GS, Baron M, King BR, Bossowski JP, Bjornberg A, Pour M, et al. Cellular adaptation to cancer therapy along a resistance continuum. Nature. 8022;631(8022):876\u201383.","journal-title":"Nature"},{"issue":"1","key":"1690_CR69","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020;11(1):2393.","journal-title":"Nat Commun"},{"issue":"39","key":"1690_CR70","doi-asserted-by":"publisher","first-page":"e2507962122","DOI":"10.1073\/pnas.2507962122","volume":"122","author":"KJ Card","year":"2025","unstructured":"Card KJ, Crozier D, Durmaz A, Gray J, Creary J, Stocks A, et al. Evolution under vancomycin selection drives divergent collateral sensitivity patterns in Staphylococcus aureus. Proc Natl Acad Sci U S A. 2025;122(39):e2507962122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9_Supplement","key":"1690_CR71","doi-asserted-by":"publisher","first-page":"PS12-02-PS12-02","DOI":"10.1158\/1538-7445.SABCS23-PS12-02","volume":"84","author":"R Jeselsohn","year":"2024","unstructured":"Jeselsohn R, Fu J, Ren Y, Mahtani R, Ma C, DeMichele A, et al. Abstract PS12\u201302: exploration of ctDNA dynamics in the PACE trial: a randomized phase II study of fulvestrant, palbociclib, and avelumab for HR+\/HER2- metastatic breast cancer. Cancer Res. 2024;84(9_Supplement):PS12-02-PS12-02.","journal-title":"Cancer Res"},{"issue":"3","key":"1690_CR72","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427-38 e6.","journal-title":"Cancer Cell"},{"issue":"2","key":"1690_CR73","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","volume":"39","author":"E Dhimolea","year":"2021","unstructured":"Dhimolea E, de Matos Simoes R, Kansara D, Al\u2019Khafaji A, Bouyssou J, Weng X, et al. An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell. 2021;39(2):240-56 e11.","journal-title":"Cancer Cell"},{"key":"1690_CR74","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1186\/1471-2164-12-593","volume":"12","author":"CS Ross-Innes","year":"2011","unstructured":"Ross-Innes CS, Brown GD, Carroll JS. A co-ordinated interaction between CTCF and ER in breast cancer cells. BMC Genomics. 2011;12:593.","journal-title":"BMC Genomics"},{"issue":"5","key":"1690_CR75","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1541-7786.MCR-15-0423","volume":"14","author":"L Malorni","year":"2016","unstructured":"Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, et al. Blockade of AP-1 potentiates endocrine therapy and overcomes resistance. Mol Cancer Res. 2016;14(5):470\u201381.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"1690_CR76","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","volume":"132","author":"M Lupien","year":"2008","unstructured":"Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell. 2008;132(6):958\u201370.","journal-title":"Cell"},{"issue":"23","key":"1690_CR77","doi-asserted-by":"publisher","first-page":"11437","DOI":"10.1073\/pnas.1819155116","volume":"116","author":"D Chi","year":"2019","unstructured":"Chi D, Singhal H, Li L, Xiao T, Liu W, Pun M, et al. Estrogen receptor signaling is reprogrammed during breast tumorigenesis. Proc Natl Acad Sci U S A. 2019;116(23):11437\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"1690_CR78","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1101\/gad.1446006","volume":"20","author":"J Eeckhoute","year":"2006","unstructured":"Eeckhoute J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown MA. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006;20(18):2513\u201326.","journal-title":"Genes Dev"},{"issue":"4","key":"1690_CR79","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/onc.2013.569","volume":"34","author":"AR Cyr","year":"2015","unstructured":"Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Woodfield GW, et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene. 2015;34(4):436\u201344.","journal-title":"Oncogene"},{"issue":"19","key":"1690_CR80","doi-asserted-by":"publisher","first-page":"9453","DOI":"10.1073\/pnas.1821068116","volume":"116","author":"Z Ji","year":"2019","unstructured":"Ji Z, He L, Regev A, Struhl K. Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers. Proc Natl Acad Sci U S A. 2019;116(19):9453\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"1690_CR81","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246\u201356.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1690_CR82","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392(12):1189\u2013202.","journal-title":"N Engl J Med"},{"key":"1690_CR83","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/978-3-031-70875-6_23","volume":"1464","author":"I Migliaccio","year":"2025","unstructured":"Migliaccio I, Guarducci C, Malorni L. CDK4\/6 inhibitor resistance in ER+ breast cancer. Adv Exp Med Biol. 2025;1464:475\u201393.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"1690_CR84","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.ccell.2021.08.007","volume":"39","author":"R Jeselsohn","year":"2021","unstructured":"Jeselsohn R, Schiff R, Grinshpun A. Restoring order at the cell cycle border: co-targeting CDK4\/6 and CDK2. Cancer Cell. 2021;39(10):1302\u20135.","journal-title":"Cancer Cell"},{"issue":"10226","key":"1690_CR85","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817\u201327.","journal-title":"Lancet"},{"issue":"17","key":"1690_CR86","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218\u201324.","journal-title":"Clin Cancer Res"},{"issue":"34","key":"1690_CR87","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1690_CR88","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-23-0705","volume":"83","author":"J Navarro-Yepes","year":"2023","unstructured":"Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, et al. Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Res. 2023;83(19):3264\u201383.","journal-title":"Cancer Res"},{"issue":"9","key":"1690_CR89","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43(9):1101\u201312.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1690_CR90","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R, Domrachev M, Lash AE. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207\u201310.","journal-title":"Nucleic Acids Res"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01690-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01690-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:02:17Z","timestamp":1789610537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01690-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01690-2","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All samples included in this study were voluntarily donated by patients who provided informed consent under an IRB-approved protocol (Dana-Farber\/Harvard Cancer Center no. 05\u2013246) and patient consent in accordance with the Helsinki Declaration. The protocol includes permission for sample acquisition, clinical data abstraction, sample analysis and data sharing. Analysis of biospecimens at the Broad Institute was performed under Broad Institute protocol number 15-370B.All mice were maintained in accordance with local guidelines and therapeutic interventions approved by the Animal Care and Use Committees of Dana-Farber Cancer Institute Protocol # 04-111.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AN is an AstraZeneca employee; JGTZ reported ownership of stocks in the biotechnology exchange-traded funds CNCR, IDNA, IBB, and XBI; owns stocks in Novo Nordisk and GRAIL; and previously owned stocks in Adaptive Biotechnologies, 2seventy bio, and bluebird bio; NUL has received research support paid to her institution from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca. She has received honoraria for consulting work from Seattle Genetics, Daichii-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline\/Menarini, Eisai, Shorla Oncology. She holds stock options in Artera Inc (unrelated to breast cancer or brain metastases research) and receives royalties from UpToDate (book chapter). She receives travel support from Olema, AstraZeneca and Daichii Sankyo; SMT reports consulting or advisory roles for\u202fNovartis, Pfizer\/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech\/Roche, Eisai, Bristol Myers Squibb\/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini\/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Launch Therapeutics, Zuellig Pharma, Johnson&Johnson\/Ambrx, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summitt Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema; research funding Genentech\/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, NanoString Technologies, Gilead, SeaGen, OncoPep, Daiichi Sankyo, Menarini\/Stemline, Jazz Pharmaceuticals; and travel support from Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, Roche; LM reports advisory role for AstraZeneca, Pfizer, Lilly, Novartis, Seagen, Roche and Menarini, fundings from Pfizer, Novartis and travel grants from Pfizer and Gilead; PS has been a consultant at Novartis, Genovis, Guidepoint, The Planning Shop, ORIC Pharmaceuticals, Cedilla Therapeutics, Syros Pharmaceuticals, Blueprint Medicines, Curie Bio, Differentiated Therapeutics, Excientia, Ligature Therapeutics, Merck, Redesign Science, Scorpion Therapeutics, Incyte, Serinus Biosciences, Meliora Therapeutics, Sibylla Biotech, Exo Therapeutics and Astex Pharmaceuticals; KP serves on the Scientific Advisory Board of Ideaya Biosciences, is an adviser to Curie.Bio and Redona Therapeutics, holds equity in Antares Therapeutics and stock options in Ideaya Biosciences, receives sponsored research funding from Novartis, and received honoraria from Astra-Zeneca in the past 12\u00a0months; CP is a consultant for XSphera Biosciences and has stock and other ownership interests in XSphera Biosciences. Received honoraria from Thermo Fisher and Agilent and has sponsored research agreements with Daiichi Sankyo, Bicycle Therapeutics, Transcenta, Bicara Therapeutics, AstraZeneca, Janssen Pharmaceuticals, Array Biopharma, Takeda Onkology, Bristol Meyers Squibb, TargImmune, and Mirati Therapeutics; FM is a co-founder of and has equity in Harbinger Health, has equity in Zephyr AI, and serves as a consultant for both companies. She is also on the board of directors of Recursion Pharmaceuticals. She declares that none of these relationships are directly or indirectly related to the content of this manuscript. GG receives research funds from IBM, Pharmacyclics\/Abbvie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite, and Novartis and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye, MinimuMM-seq, and DLBclass. He is a founder, consultant, and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in, Predicta Biosciences; and holds privately held equity in Antares Therapeutics. RJ reports consulting or advisory role for Eli Lilly, Astra Zeneca, Pfizer, Novartis, Carrick Therapeutics, GE Health, and Luminex and research funding from Pfizer, Eli Lilly, and Novartis.All other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"134"}}